Thomas R. Carper bought Novo Nordisk A/S (NYSE: NVO)
Thomas R. Carper (D-DE), a U.S. Senator, has disclosed 1 trade in Novo Nordisk A/S (NVO) since 2020, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Thomas R. Carper bought $1,001 - $15,000 of Novo Nordisk A/S (NYSE: NVO) on April 2, 2020. Since that trade, NVO is up +97.93% against the S&P 500 up +215.12%, an outperformance of -117.19%.
Data updated
Thomas R. Carper's NVO trades vs the price
NVO is up +97.93% since Thomas R. Carper bought on April 2, 2020, versus +215.12% for the S&P 500.
Performance since this trade
All Thomas R. Carper NVO trades
Thomas R. Carper & NVO trading FAQ
Is it legal for Thomas R. Carper to trade Novo Nordisk A/S (NVO) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novo Nordisk A/S (NVO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Thomas R. Carper buy NVO?
Thomas R. Carper disclosed a purchase of $1,001 - $15,000 of Novo Nordisk A/S (NVO) on April 2, 2020, according to public STOCK Act filings.
How has NVO performed since Thomas R. Carper's trade?
Since Thomas R. Carper bought NVO on April 2, 2020, the stock is up +97.93%, versus +215.12% for the S&P 500 over the same period, an outperformance of -117.19%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVO trades?
Quantellect tracks every disclosed congressional trade in Novo Nordisk A/S (NVO) on the Novo Nordisk A/S congressional trading page, which aggregates filings across all members of Congress.
Thomas R. Carper's NVO tradesAll congressional filings for Novo Nordisk A/SThomas R. Carper's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.